hu-210 has been researched along with Multiple-Sclerosis* in 1 studies
1 other study(ies) available for hu-210 and Multiple-Sclerosis
Article | Year |
---|---|
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.
Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacological approach in the treatment of various diseases due to the absence of relevant psychoactive side effect. In this study, we synthesized and tested a series of new quinoline-2(1H)-one- and 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by a 4-methylcyclohexylamido substituent in position 3 of the heterocyclic nucleus with high CB2 receptor affinity and selectivity. Two compounds showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concentration-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor. Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compounds were studied for their potential immune-modulatory and anti-inflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients. Topics: Amides; Anti-Inflammatory Agents; Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Survival; Humans; Male; Molecular Structure; Multiple Sclerosis; Naphthyridines; Prostatic Neoplasms; Quinolines; Receptor, Cannabinoid, CB2; Reference Standards | 2015 |